



SEQUENCE LISTING

<110> Nasoff, Marc
Deveraux, Quinn L.
Knee, Deborah A.
Aza-Blanc, Pedro
Hampton, Garret M.
Wagner, Klaus
IRM LLC

<120> Methods and Compositions for Inducing Apoptosis in
Cancer Cells

<130> 021288-002920US

<140> US 10/723,383
<141> 2003-11-25

<150> US 60/429,842
<151> 2002-11-27

<150> US 448,960
<151> 2003-02-21

<150> US 60/494,714
<151> 2003-08-12

<150> US 60/504,901
<151> 2003-09-22

<160> 15

<170> PatentIn Ver. 2.1

<210> 1
<211> 64
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Baculovirus
Inhibitory Repeat (BIR) region motif conserved
residue consensus sequence

<220>
<221> MOD_RES
<222> (2)..(24)
<223> Xaa = any amino acid, Xaa at positions 22-24 may
be present or absent

<220>
<221> MOD_RES
<222> (26)..(36)
<223> Xaa = any amino acid

<220>
<221> MOD_RES
<222> (38)..(39)
<223> Xaa = any amino acid

```
<220>
<221> MOD_RES
<222> (41)..(56)
<223> Xaa = any amino acid

<220>
<221> MOD_RES
<222> (58)..(63)
<223> Xaa = any amino acid
```

```
<400> 1
Arg Xaa Xaa
1 5 10 15
```

```
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
```

```
Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
```

```
Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Cys
50 55 60
```

```
<210> 2
<211> 359
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence:anti-DR5
      Antibody A light chain variable region
```

```
<400> 2
gacattgcga tgacctcagtc tcacaaggatc atgtccacat tagtgggaga cagggtcagc 60
atcacctgca aggccagtca ggatgtaat actgctatacg cctggtatca acaaaaaacca 120
ggccaatctc ctaaaactact gatttactgg gcatccaccc ggcacactgg agtcccctgat 180
cgcttcacag gcagtggtac tgggacagat tatactctca ccatcagcag tatggaggct 240
gaagatgctg ccacttatta ctgccagcag tggagtagta acccgctcac gttcggtgct 300
gggaccaagc tggagctgaa acgggctgtat gctgcaccaa ctgtatccat cttcccacc 359
```

```
<210> 3
<211> 360
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence:anti-DR5
      Antibody A heavy chain variable region
```

```
<400> 3
caggcaaagg tccagctgca gcagtctgga gctgagctgg tgaaacccgg ggcatcagtg 60
aagctgtcct gcaaggcttc tggctacacc ttcaactgact atactataca ctgggtaaag 120
cagaggctcg gacagggtct tgagtggatt ggggtggttt accctggagg tggttatata 180
aaatacaatg agaaattcaa ggacagggcc acattgactg cggacaaaatc ctccaacaca 240
gtctatatgg agcttagtcg attgacatct gaaggctctg cggcttattt ctgtgcaaga 300
cacgaagagg gcatctatgg tgactactgg ggccaaggca ccactctcac agtctcctca 360
```

```

<210> 4
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:anti-DR5
      Antibody A heavy chain subgroup B variable region

<400> 4
Lys Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
  1           5           10          15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
  20          25          30

Thr Ile His Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile
  35          40          45

Gly Trp Phe Tyr Pro Gly Gly Tyr Ile Lys Tyr Asn Glu Lys Phe
  50          55          60

Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Val Tyr
  65          70          75          80

Met Glu Leu Ser Arg Leu Thr Ser Glu Gly Ser Ala Val Tyr Phe Cys
  85          90          95

Ala Arg His Glu Glu Gly Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
  100         105         110

Thr Leu Thr Val Ser Ser
  115

<210> 5
<211> 109
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:anti-DR5
      Antibody A kappa light chain subgroup 5 variable
      region

<400> 5
Asp Ile Ala Met Thr Gln Ser His Lys Phe Met Ser Thr Leu Val Gly
  1           5           10          15

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala
  20          25          30

Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
  35          40          45

Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
  50          55          60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Met Glu Ala
  65          70          75          80

```

Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu
85 90 95

Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala
100 105

<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthetic siRNA
ttds(N)19TT

<220>
<221> modified_base
<222> (3)..(21)
<223> n = any nucleotide

<400> 6
ttnnnnnnnn nnnnnnnnn ntt 23

<210> 7
<211> 354
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:alternate
sequence for anti-DR5 Antibody A heavy chain
variable region

<400> 7
aaggccagc tgcagcagtc tggagctgag ctgggtgaaac ccggggcatc agtgaagctg 60
tcctgcaagg cttctggcta caccttcaact gactatacta tacactgggt aaagcagagg 120
tctggacagg gtcttgagtg gattgggtgg ttttaccctg gaggtggta tataaaatac 180
aatgagaaat tcaaggacag ggccacattg actgcggaca aatcctccaa cacagtctat 240
atggagctta gtcgattgac atctgaagac tctgcggctt atttctgtgc aagacacgaa 300
gagggcatct atttgacta ctggggccaa ggcaccactc tcacagtctc ctca 354

<210> 8
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:alternate
sequence for anti-DR5 Antibody A heavy chain
variable region

<400> 8
Lys Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Thr Ile His Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Trp Phe Tyr Pro Gly Gly Gly Tyr Ile Lys Tyr Asn Glu Lys Phe
50 55 60

Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Val Tyr
65 70 75 80

Met Glu Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg His Glu Glu Gly Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

Thr Leu Thr Val Ser Ser
115

<210> 9
<211> 312
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:alternate
sequence for anti-DR5 Antibody A light chain
variable region

<400> 9
gacattgtga tgaccaggc tcacaaggcc atgtccacat cagtggaga cagggtcagc 60
atcacctgca aggccaggta ggtatgtaat actgctatacg cctggtatca acaaaaacca 120
gggcaatctc ctaaaactact gatttactgg gcatccaccc ggcacactgg agtcccctgat 180
cgcttcacag gcagtggtatc tgggacagat tatactctca ccatcagcag tgtgcaggct 240
gaagacctgg cactttatta ctgtcagcaa cattatacca ctccattcac gttcggctcg 300
gggacaaagt tg 312

<210> 10
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:alternate
sequence for anti-DR5 Antibody A light chain
variable region

<400> 10
Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala
20 25 30

Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80
Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Phe
85 90 95
Thr Phe Gly Ser Gly Thr Lys Leu
100

<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: siPAK1-0 siRNA
directed against PAK1

<400> 11
agagctgcta cagcatcaa 19

<210> 12
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: siPAK1-1 siRNA
directed against PAK1

<400> 12
gacauccaac agccagaaa 19

<210> 13
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: siPAK1-2 siRNA
directed against PAK1

<400> 13
gagaaaagagc ggccagaga 19

<210> 14
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: hPAK1-6 siRNA
directed against PAK1

<400> 14
uaccagcacu augauugga 19

<210> 15
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: siPAK1-7 siRNA
directed against PAK1

<400> 15
ucuguauaca cacggucug

19